SEC Form 4 · accession 0000899243-16-010867

USMD Holdings, Inc. · USMD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Dec 31, 2015

Accepted (ET)

Jan 5, 2016 · 5:17 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001507881

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock ($.01 par)^F1	Dec 31, 2015	J	7,143	$7.00	A	132,018	I	Indirectly held through UANT Ventures, L.P.
Common Stock ($.01 par)^F2	Dec 31, 2015	J	17	$84.75	A	132,035	I	Indirectly held through UANT Ventures, L.P.
Common Stock ($.01 par)^F3	Dec 31, 2015	J	4,033	—	D	128,002	I	Indirectly held through UANT Ventures, L.P.
Common Stock ($.01 par)	holding	—	—		—	19,228	D
Common Stock ($.01 par)	holding	—	—		—	13,248	I	Held in M. Patrick Collini, MD, P.A.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Options to Purchase^F3	$24.84	Dec 31, 2015	J	71	D	Aug 31, 2012	Aug 31, 2017	Common Stock ($.01 par)	1,749	1,749	I

F1Dr. Collini purchased additional partnership interests in UANT Ventures, L.P. ("Ventures"), which resulted in an increase in his indirect beneficial ownership of the shares of the issuer's common stock held by Ventures.
F2Ventures reallocated certain of its partnership interests among its partners based upon the results of a capital call. Dr. Collini received additional partnership interests as a result of this reallocation, which resulted in an increase in his indirect beneficial ownership of the shares of the issuer's common stock held by Ventures.
F3Ventures issued partnership interests to certain individuals and the issuance of these interests was dilutive to the ownership of Ventures held by certain of the existing partners, including Dr. Collini. This reduction in Dr. Collini's ownership of Ventures resulted in a corresponding decrease in his indirect beneficial ownership of shares and options to purchase shares of the issuer's common stock held by Ventures. No consideration was paid and Dr. Collini did not receive any consideration as a result of the transaction.